Mangaluru witnesses another murder: Target Gang Ilyas on bail hacked to death

Bengaluru, Apr 5: The COVID-19 related lockdown has substantially improved the air quality of Bengaluru, taking it from satisfactory level to good, a senior state pollution control board offcial said here on Sunday.

"During the course of the lockdown 19 problem, we reached good position from satisfactory.

It is between zero to 50 AQI (Air Quality Index) now. We have good quality air," the Karnataka State Pollution Control Board member secretary Basavaraj Patil told PTI.

He said the indicator for knowing the air quality in

"If the AQI is zero to 50 then it is good. If it is 50 to 100 then it is satisfactory. 101 to 150 is moderate and if it is 151 to 200, then it is poor, he explained.

Patil said as per available recrods, there has been a 60 to 65 per cent reduction in pollution during the lockdown.

The city railway station and Peenya industrial area, which used to be among the areas with highest AQI, has seen pollution levels come down significantly, he said.

Another major contributor of pollution was construction activities, which too had ground to a halt due to the lockdown, resulting in zero dust emission.

Patil opined that the improved air quality would boost the immune system of the people.

"It will improve the immune system of people, including those who have breathing problems like asthma," he said.

He asked the public to learn lessons from the lockdown and later switch to sustainable means of transport such as public transport, walking and cycling,.

"We can still reduce the pollution load even after the lockdown is over," Patil said.

Mangaluru, Feb 27: An utterly unprofessional thief, who fell asleep after breaking into a house, was caught by the house owner and handed over to the police in the coastal district of Dakshina Kannada.

The hilarious incident took place on Wednesday in the one-storey, tiled-roof house owned by Sudarshan at Ullas Junction under the limits of Uppinangady police station.

The thief, who gained entry into the house by removing the roof-tiles, has been identified as Anil Sahani, a native of Bihar’s Majipur district. He was snoring on the sofa with a set of keys clutched in his hand when the house owner woke up in the morning.

The house owner, who was sure that the thief was drunk, woke him up by hitting him with a stick and then handed him over to the police.

According to police, the thief was tired after removing the tiles on Tuesday night and hence he decided to take a nap soon after entering the house.

He grabbed a bunch of keys kept near the TV stand and then lied down on the sofa. He woke up only when the house owner hit him with a stick the next morning.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.